These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 16368879)

  • 1. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
    Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
    Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.
    Zhou H; Luo Y; Lo JF; Kaplan CD; Mizutani M; Mizutani N; Lee JD; Primus FJ; Becker JC; Xiang R; Reisfeld RA
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10846-51. PubMed ID: 16040807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
    Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
    Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
    Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
    J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cells contribute to the skin graft rejection promoted by CD4+ T cells activated through the indirect allorecognition pathway.
    Ito A; Shimura H; Nitahara A; Tomiyama K; Ito M; Kanekura T; Okumura K; Yagita H; Kawai K
    Int Immunol; 2008 Oct; 20(10):1343-9. PubMed ID: 18697765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
    Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.
    Draghi M; Pashine A; Sanjanwala B; Gendzekhadze K; Cantoni C; Cosman D; Moretta A; Valiante NM; Parham P
    J Immunol; 2007 Mar; 178(5):2688-98. PubMed ID: 17312110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the NKG2D immunoreceptor in immune cell activation and natural killing.
    Jamieson AM; Diefenbach A; McMahon CW; Xiong N; Carlyle JR; Raulet DH
    Immunity; 2002 Jul; 17(1):19-29. PubMed ID: 12150888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
    Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction.
    Adam C; King S; Allgeier T; Braumüller H; Lüking C; Mysliwietz J; Kriegeskorte A; Busch DH; Röcken M; Mocikat R
    Blood; 2005 Jul; 106(1):338-44. PubMed ID: 15769894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis.
    Ito Y; Kanai T; Totsuka T; Okamoto R; Tsuchiya K; Nemoto Y; Yoshioka A; Tomita T; Nagaishi T; Sakamoto N; Sakanishi T; Okumura K; Yagita H; Watanabe M
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G199-207. PubMed ID: 17962357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
    Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
    Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKG2D stimulation of CD8
    Kavazović I; Lenartić M; Jelenčić V; Jurković S; Lemmermann NAW; Jonjić S; Polić B; Wensveen FM
    Eur J Immunol; 2017 Jul; 47(7):1123-1135. PubMed ID: 28378389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
    Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
    Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of V gamma 9V delta 2 T cells by NKG2D.
    Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
    J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells.
    Liu K; Idoyaga J; Charalambous A; Fujii S; Bonito A; Mordoh J; Wainstok R; Bai XF; Liu Y; Steinman RM
    J Exp Med; 2005 Dec; 202(11):1507-16. PubMed ID: 16330814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
    J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
    Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
    Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
    Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
    Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.